Big Pharma and academia cement big deals in the quest for bigger prizes With the patents of many highly profitable blockbuster drugs expiring over the course of a few years, the search is on for new drugs to fill large pharmaceutical companies’ shrinking product portfolios. For years, Big Pharma has turned to smaller biotech companies… Continue Reading
Category Archives: Biotech
Subscribe to Biotech RSS FeedMoFo BioMeter Report for Q4 and Full Year 2012
Posted on by Stephen Thau and Anelia DelchevaThe fourth quarter of 2012 saw an uptick in BioMeter value, with an average BioMeter value of approximately $26.8 million for license and collaboration agreements announced during the quarter, led by an increase in BioMeter values for Phase 2 transactions and a single high-value transaction for an approved product. Transactions for Phase 2 and pre-clinical/discovery… Continue Reading
Introducing the MoFo BioMeter
Posted on by Stephen Thau and Anelia DelchevaMorrison & Foerster is pleased to introduce the MoFo BioMeter™, an index developed to measure the health of the biotechnology industry. BioMeter takes the pulse of the industry by looking at a key measure of deal value—up-front payments—for deals in all stages of development. We also offer insight on the data and the potential impacts… Continue Reading
A Breed Apart
Posted on from MoFo Tech Fall/Winter 2012Crop inventors are seeking to protect their work, even if they don’t use GMOs When international seed supplier Enza Zaden bred a delicious and juicy new tomato in the 1990s, the world was introduced to the now famous Campari. The globe-shaped vegetable soon became a supermarket staple, but the Dutch company did not patent its… Continue Reading
Biotech’s Reprieve: A federal panel rules that isolated DNA really are different
Posted on from MoFo Tech Fall/Winter 2011The biotech industry has been built on three decades of gene patenting, so it was thrown for a loop a year ago when a federal judge ruled that DNA isolated from the body were “products of nature” and therefore could not be patented. On July 29 a federal appeals court overturned that ruling against Myriad… Continue Reading